4McCartney SVermi W, Gilfillan S, Cella M, etal. Distinct and complementary functions of MDA5 and TLR3 inpoly (I:C)-mediated activation of mouse NK cells[J].Exp Med, 2009, 206: 2967-2976.
5Kenney RT, Cross AS.Adjuvants for the future.In ~ New Generation Vaccines[J].New York:Informa Healthcare USA,Inc., 2010: 250-262.
6Glenny A, Pope C, Waddington H, etal.The anti- gentic value of toxoid precipitated by potassium alum[J|.J Pathol Bacterial, 1926, 29: 38-45.
7Anthony C A. Noelene E B.Immunological adju- vants:desirable properties and side-effects[J]. Mol Immunol, 1991, 28(3):279-284.
8Aikawa K, Matsumoto .K, Uda H, et al.Prolonged release of drug from O/W emulsion and resi- dence in rat nasal cavity[J].Pharm Dev Technol, 1998, 3(4):461-469.
9Kersten G F,Crommelin D J.Liposomes and IS- COMs[J].Vaccine, 2003, 21: 915-920.
10Abusugra I, Wolf G, Bolsker G, etal.ISCOM vac- cine against contagious bovine pieuropneumonia (CBPP)[J],Veterinary Immunology and Immuopa- thology, 1997, 59(12): 31-48.
